Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge

被引：26

作者：

Triulzi, Tiziana ^{[1
]}

Bianchi, Giulia Valeria ^{[2
]}

Tagliabue, Elda ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Targeting Unit, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 11期

关键词：

biomarkers; breast cancer; clinical trials; estrogen receptor; HER2; immune cells; trastuzumab; GROWTH-FACTOR RECEPTOR; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; PLUS ADJUVANT CHEMOTHERAPY; TRASTUZUMAB RESISTANCE; MONOCLONAL-ANTIBODY; OPEN-LABEL; NEOADJUVANT THERAPY; PREOPERATIVE TRASTUZUMAB; IMMUNE SIGNATURE;

D O I：

10.2217/fon-2015-0025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The transmembrane tyrosine kinase receptor HER2 is overexpressed in 20% of invasive breast cancers and is associated with more aggressive disease. Until the advent of targeted agents, HER2 was associated with worse outcome. Trastuzumab, a recombinant humanized anti-HER2 monoclonal antibody, combined with chemotherapy improves disease-free and overall survival in both primary and metastatic tumors and represents a foundation of care for patients with HER2-positive breast cancers. However, a sizeable number of patients do not respond to this reagent, indicating the need for a biomarker able to recognize resistant tumors. Here, we review various studies on mechanisms of action and resistance to trastuzumab that have proven relevant in understanding how tumor care can be tailored to all HER2-positive patients.

引用

页码：1413 / 1428

页数：16

共 103 条

[1] Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant [J].

Alajati, Abdullah ;

Sausgruber, Nina ;

Aceto, Nicola ;

Duss, Stephan ;

Sarret, Sophie ;

Voshol, Hans ;

Bonenfant, Debora ;

Bentires-Alj, Mohamed .

CANCER RESEARCH, 2013, 73 (17) :5320-5327

[2] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Andre, Fabrice ;

O'Regan, Ruth ;

Ozguroglu, Mustafa ;

Toi, Masakazu ;

Xu, Binghe ;

Jerusalem, Guy ;

Masuda, Norikazu ;

Wilks, Sharon ;

Arena, Francis ;

Isaacs, Claudine ;

Yap, Yoon-Sim ;

Papai, Zsuzsanna ;

Lang, Istvan ;

Armstrong, Anne ;

Lerzo, Guillermo ;

White, Michelle ;

Shen, Kunwei ;

Litton, Jennifer ;

Chen, David ;

Zhang, Yufen ;

Ali, Shyanne ;

Taran, Tetiana ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (06) :580-591

[3] Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation [J].

Anido, Judit ;

Scaltriti, Maurizio ;

Bech Serra, Joan Josep ;

Santiago Josefat, Belen ;

Rojo Todo, Federico ;

Baselga, Jose ;

Arribas, Joaquin .

EMBO JOURNAL, 2006, 25 (13) :3234-3244

[4]

[Anonymous], J CLIN ONCOL S

[5] Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[6] Protein ectodomain shedding [J].

Arribas, J ;

Borroto, A .

CHEMICAL REVIEWS, 2002, 102 (12) :4627-4637

[7] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[8] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[9] Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial [J].

Bianchini, G. ;

Pusztai, L. ;

Pienkowski, T. ;

Im, Y. -H. ;

Bianchi, G. V. ;

Tseng, L. -M. ;

Liu, M. -C. ;

Lluch, A. ;

Galeota, E. ;

Magazzu, D. ;

de la Haba-Rodriguez, J. ;

Oh, D. -Y. ;

Poirier, B. ;

Pedrini, J. L. ;

Semiglazov, V. ;

Valagussa, P. ;

Gianni, L. .

ANNALS OF ONCOLOGY, 2015, 26 (12) :2429-2436

[10] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

← 1 2 3 4 5 6 7 8 9 10 →